Clinical TrialJun 12, 2026, 04:37 PM
Lineage Cell Withdraws CIRM Grant Application for OPC1
AI Summary
Lineage Cell Therapeutics withdrew its application for a Clinical Trial (CLIN2) award from the California Institute for Regenerative Medicine (CIRM) to support the clinical development of OPC1 for spinal cord injuries. The company stated this withdrawal does not impact its current and planned development of OPC1. Additionally, at its annual meeting, shareholders elected seven directors, ratified Baker Tilly US, LLP as the independent registered public accounting firm for 2026, and approved executive officer compensation on an advisory basis.
Key Highlights
- Lineage Cell withdrew its CIRM Grant application for OPC1's clinical development.
- The withdrawal does not impact current or planned OPC1 development in the DOSED clinical study.
- Shareholders elected seven director nominees to the board until the 2027 annual meeting.
- Baker Tilly US, LLP was ratified as the independent auditor for fiscal year 2026 with 163,825,928 votes for.
- Executive officer compensation was approved on an advisory basis with 88,328,168 votes for.
Price Impact
More from LCTX